Stavudine
- Generic Name
- Stavudine
- Brand Names
- Zerit
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12N2O4
- CAS Number
- 3056-17-5
- Unique Ingredient Identifier
- BO9LE4QFZF
- Background
A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.
- Indication
For the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- Human Immunodeficiency Virus (HIV) Infections
- Associated Therapies
- -
A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants
Phase 1
Completed
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 26
- Registration Number
- NCT00000878
- Locations
- 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸Univ of Chicago Children's Hosp, Chicago, Illinois, United States
🇺🇸Children's Hosp of Boston, Boston, Massachusetts, United States
A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone
Phase 2
Completed
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 200
- Registration Number
- NCT00000870
- Locations
- 🇺🇸
The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States
🇺🇸Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
🇺🇸Case CRS, Cleveland, Ohio, United States
A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy
Phase 4
Completed
- Conditions
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath